Peptimmune Report issue

For profit Phase 1
Founded: Cambridge MA United States (1997)
Status: Acquired by Genzyme (1999) → now Sanofi-Aventis (2011)

Organization Overview

First Clinical Trial
2003
NCT00063752
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2003

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 1 Trials (1)

pi-0824 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pemphigus (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1